Real-world outcomes of hepatitis C treatment during the interferon-free era at an urban safety-net hospital

Abstract

Background. Little is known about real-world outcomes for new interferon-free treatment for hepatitis C virus (HCV) among underserved and diverse communities. Objective. To identify predictors of treatment prescription and evaluate outcomes as measured by sustained virologic response (SVR) with HCV RNA testing three months after therapy completion. Design. Retrospective cohort at a safety-net health care system. Participants. Patients with (1) at least one clinical visit between December 6, 2013, and December 31st 2014; and (2) at least three months follow-up. Key results. Predominantly non-White cohort (61%). Of 1,284 HCV-infected patients 121 prescribed sofosbuvir-based therapy. Severe liver fibrosis (OR 1.66, 95% CI 1.05, 2.64) independently associated with treatment prescription. In those with evaluable HCV RNA, SVR was 99%. Conclusion. Cure rates similar to clinical trial data can be achieved in diverse underserved communities.